Mode of Action of SQSTM1 Mutations in Paget's Disease Bone
Project Number1R21AR054161-01
Contact PI/Project LeaderHANSEN, MARC F.
Awardee OrganizationUNIVERSITY OF CONNECTICUT SCH OF MED/DNT
Description
Abstract Text
DESCRIPTION (provided by applicant): Paget's Disease of bone is a condition in which rapid bone formation occurs, altering the strength and shape of the bone. Predisposition to familial Paget's Disease has been linked to a number of loci, including the Sequestosome 1 (SQSTM1) locus where germline mutations have been identified in 40% of the familial cases. Germline SQSTM1 mutations have also been found in some apparent sporadic cases of Paget's Disease, suggesting that these may be de novo familial cases. In all but one case, the constitutional mutations have been found to be heterozygous. This suggests that the mutation may be acting in a dominant manner. However, it is also possible that the mutation is acting as a dominant negative or haploinsufficiency mutation, or as a recessive mutation that has undergone loss of heterozygosity in the affected bone. We were curious as to the nature of the mutation in the affected bone. We chose to examine the SQSTM1 locus in the affected bones of sporadic patients to see: 1) whether somatic mutations in SQSTM1 occurred in these bones and 2) whether the mutation was heterozygous or homozygous in the affected bone. When we sequenced the SQSTM1 gene in both the affected bone and matched peripheral blood, we found a P392L mutation in 4 of 5 samples of affected bone and none of the matched blood samples. What was more surprising was that in the affected bone, the relative frequency of the P392L mutation in the samples ranged from 10% to 28%, suggesting that the bone was mosaic for the mutation. The relative frequency of the mutation in each individual sample was consistent upon repeated resampling and resequencing. Next, since osteosarcoma is a complication of Paget's Disease, we were curious to see whether SQSTM1 mutations were present in pagetic osteosarcomas. When we screened the SQSTM1 gene in these tumors, we found that 4 of 5 osteosarcomas had homozygous P392L mutations. Again, no mutations were detected in the matched normal bone. Together, this evidence causes a paradigm shift in our model of Paget's Disease. It suggests that while mutations in SQSTM1 are predisposing in familial Paget's Disease, they are not the initiating event in sporadic Paget's Disease. Secondly, this suggested that the tumors arose from osteoblastic cells that contained the SQSTM1 mutation and that osteoblasts play a role in the etiology of Paget's Disease. Our hypothesis is that mutations in SQSTM1 occur somatically in a subset of osteoblast-like cells in pagetic bone and that these somatic mutations become homozygous during pagetic osteosarcoma tumorigenesis. To test this hypothesis, we propose the following specific aims: 1) To test whether somatic SQSTM1 mutations are heterozygous and clonal in the pagetic bone. 2) To test whether loss of heterozygosity at the SQSTM1 locus occurs in the pagetic bone or during pagetic tumorigenesis.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
022254226
UEI
H6D6JMXJXDE6
Project Start Date
15-July-2006
Project End Date
30-June-2008
Budget Start Date
15-July-2006
Budget End Date
30-June-2007
Project Funding Information for 2006
Total Funding
$162,800
Direct Costs
$110,000
Indirect Costs
$52,800
Year
Funding IC
FY Total Cost by IC
2006
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$162,800
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21AR054161-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21AR054161-01
Patents
No Patents information available for 1R21AR054161-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21AR054161-01
Clinical Studies
No Clinical Studies information available for 1R21AR054161-01
News and More
Related News Releases
No news release information available for 1R21AR054161-01
History
No Historical information available for 1R21AR054161-01
Similar Projects
No Similar Projects information available for 1R21AR054161-01